Inhibition of SGLT2 alleviates diabetic nephropathy by suppressing high glucose-induced oxidative stress in type 1 diabetic mice

Pharmacology Research and Perspectives

Volumn 4, Issue 4, 2016, Pages

  Hatanaka, Takashi ^a   Ogawa, Daisuke ^a   Tachibana, Hiromi ^a   Eguchi, Jun ^a   Inoue, Tatsuyuki ^a   Yamada, Hiroshi ^a   Takei, Kohji ^a   Makino, Hirofumi ^a   Wada, Jun ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Diabetic nephropathy; hyperglycemia; oxidative stress; SGLT2 inhibitor; urinary albumin excretion

Indexed keywords

ALBUMIN; COLLAGEN TYPE 4; CREATININE; DAPAGLIFLOZIN; FATTY ACID; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOREACTIVE INSULIN; INSULIN GLARGINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; SODIUM GLUCOSE COTRANSPORTER 2; TRIACYLGLYCEROL;

AKITA MOUSE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS ASSAY; ARTICLE; BODY WEIGHT; CHLORIDE URINE LEVEL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG EFFECT; FIBROSING ALVEOLITIS; FLOW CYTOMETRY; FLUID INTAKE; FOOD INTAKE; GEL FILTRATION CHROMATOGRAPHY; GENE EXPRESSION ASSAY; GENE SILENCING; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; GLUCOSE URINE LEVEL; HISTOLOGY; HYPERGLYCEMIA; IMMUNOFLUORESCENCE TEST; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FUNCTION; KIDNEY MASS; KIDNEY TUBULE CELL; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SODIUM URINE LEVEL; TUNEL ASSAY; UREA NITROGEN BLOOD LEVEL; URINE VOLUME; WESTERN BLOTTING;

EID: 85019870969     PISSN: None     EISSN: 20521707     Source Type: Journal    
DOI: 10.1002/prp2.239     Document Type: Article

References (27)

1. Arakawa K, Ishihara T, Oku A, Nawano M, Ueta K, Kitamura K, et al. (2001). Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095. Br J Pharmacol 132: 578–586.
2. Bagby SP (2007). Diabetic nephropathy and proximal tubule ROS: challenging our glomerulocentricity. Kidney Int 71: 1199–1202.
3. de Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J (2011). Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 305: 2532–2539.
4. Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, et al. (2014). Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129: 587–597.
5. Collins AJ, Foley RN, Chavers B, Gilbertson D, Herzog C, Johansen K, et al. (2012). ‘United States Renal Data System 2011 Annual Data Report: atlas of chronic kidney disease & end-stage renal disease in the United States. Am J Kidney Dis 59(1 Suppl 1): A7, e1–e420.
6. Fujita H, Fujishima H, Chida S, Takahashi K, Qi Z, Kanetsuna Y, et al. (2009). Reduction of renal superoxide dismutase in progressive diabetic nephropathy. J Am Soc Nephrol 20: 1303–1313.
7. Gangadharan Komala M, Gross S, Mudaliar H, Huang C, Pegg K, Mather A, et al. (2014). Inhibition of kidney proximal tubular glucose reabsorption does not prevent against diabetic nephropathy in type 1 diabetic eNOS knockout mice. PLoS ONE 9: e108994.
8. Giacco F, Du X, D'Agati VD, Milne R, Sui G, Geoffrion M, et al. (2014). Knockdown of glyoxalase 1 mimics diabetic nephropathy in nondiabetic mice. Diabetes 63: 291–299.
9. Gregg EW, Li Y, Wang J, Burrows NR, Ali MK, Rolka D, et al. (2014). Changes in diabetes-related complications in the United States, 1990–2010. N Engl J Med 370: 1514–1523.
10. Hasan FM, Alsahli M, Gerich JE (2014). SGLT2 inhibitors in the treatment of type 2 diabetes. Diabetes Res Clin Pract 104: 297–322.
11. Henry RR, Rosenstock J, Edelman S, Mudaliar S, Chalamandaris AG, Kasichayanula S, et al. (2015). Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study. Diabetes Care 38: 412–419.
12. Kanwar YS, Sun L, Xie P, Liu FY, Chen S (2011). A glimpse of various pathogenetic mechanisms of diabetic nephropathy. Annu Rev Pathol 6: 395–423.
13. Kojima N, Williams JM, Takahashi T, Miyata N, Roman RJ (2013). Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats. J Pharmacol Exp Ther 345: 464–472.
14. Maeda S, Matsui T, Takeuchi M, Yamagishi S (2013). Sodium-glucose cotransporter 2-mediated oxidative stress augments advanced glycation end products-induced tubular cell apoptosis. Diabetes Metab Res Rev 29: 406–412.
15. Mather A, Pollock C (2010). Renal glucose transporters: novel targets for hyperglycemia management. Nat Rev Nephrol 6: 307–311.
16. Matsushita Y, Ogawa D, Wada J, Yamamoto N, Shikata K, Sato C, et al. (2011). Activation of peroxisome proliferator-activated receptor delta inhibits streptozotocin-induced diabetic nephropathy through anti-inflammatory mechanisms in mice. Diabetes 60: 960–968.
17. Morii T, Fujita H, Narita T, Shimotomai T, Fujishima H, Yoshioka N, et al. (2003). Association of monocyte chemoattractant protein-1 with renal tubular damage in diabetic nephropathy. J Diabetes Complications 17: 11–15.
18. Nagata T, Fukuzawa T, Takeda M, Fukazawa M, Mori T, Nihei T, et al. (2013). Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice. Br J Pharmacol 170: 519–531.
19. Ninichuk V, Khandoga AG, Segerer S, Loetscher P, Schlapbach A, Revesz L, et al. (2007). The role of interstitial macrophages in nephropathy of type 2 diabetic db/db mice. Am J Pathol 170: 1267–1276.
20. Panchapakesan U, Pegg K, Gross S, Komala MG, Mudaliar H, Forbes J, et al. (2013). Effects of SGLT2 inhibition in human kidney proximal tubular cells–renoprotection in diabetic nephropathy? PLoS ONE 8: e54442.
21. Ptaszynska A, Johnsson KM, Parikh SJ, de Bruin TW, Apanovitch AM, List JF (2014). Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events. Drug Saf 37: 815–829.
22. Terami N, Ogawa D, Tachibana H, Hatanaka T, Wada J, Nakatsuka A, et al. (2014). Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. PLoS ONE 9: e100777.
23. Thomas MC (2014). Renal effects of dapagliflozin in patients with type 2 diabetes. Ther Adv Endocrinol Metab 5: 53–61.
24. Tonolo G, Cherchi S (2014). Tubulointerstitial disease in diabetic nephropathy. Int J Nephrol Renovasc Dis 7: 107–115.
25. Vallon V, Rose M, Gerasimova M, Satriano J, Platt KA, Koepsell H, et al. (2013). Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus. Am J Physiol Renal Physiol 304: F156–F167.
26. Vallon V, Gerasimova M, Rose MA, Masuda T, Satriano J, Mayoux E, et al. (2014). SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Renal Physiol 306: F194–F204.
27. Wilding JP (2014). The role of the kidneys in glucose homeostasis in type 2 diabetes: clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors. Metabolism 63: 1228–1237.